Welcome to BioSeeker Group!

Triple Analysis: Lung Cancer, Lymphoma and Angiogenesis

Additional Information

Published Date Jan 30, 2012
Special Offer

You can deduct the full value of this report within 30 days of purchase towards a Cancer Highlights subscription.
Read more about becoming a Cancer Highlights subscriber here.

Pages 3981
PDF Fact Sheet View Fact Sheet for the report Triple Analysis: Lung Cancer, Lymphoma and Angiogenesis in PDF
Format PDF
Publisher BioSeeker Group
Product Line

Find the Triple Analysis Report in oncology which best suits your needs by selecting any three (3) out of these 14 high impact Cancer Focus Areas.

Availability: In stock

$3,450.00

Quick Overview

This triple analysis focuses on cancer drug development strategies in both Lung Cancer and Lymphoma and by the mechanism/target/effect of Angiogenesis.

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Lung Cancer, Lymphoma and Angiogenesis.

    To find out more about Triple Analysis: Lung Cancer, Lymphoma and Angiogenesis, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Lung Cancer, Lymphoma and Angiogenesis is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

This triple analysis focuses on cancer drug development strategies in both Lung Cancer and Lymphoma and by the mechanism/target/effect of Angiogenesis. Each of these three individual parts is evaluated according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between different areas.

Below is a short synopsis of each part included in this report:

Part I: Lung Cancer
The lung cancer report part comprises defined and up to date development strategies for 416 lung cancer drugs within the portfolio of 218 investigators, from Ceased to Marketed. This part extensively analyses their 241 identified drug targets, organized into 237 drug target strategies, and assesses them in eight different compound strategies and and three subindications of lung cancer.
This part is based on the following publication:
Lung Cancer: A Decision Support Tool for Optimizing the Pipeline from Research To Market

Part II: Lymphoma
The lymphoma report part comprises defined and up to date development strategies for 282 lymphoma drugs within the portfolio of 154 investigators, from Ceased to Marketed. This part extensively analyses their 181 identified drug targets, organized into 173 drug target strategies, and assesses them in eight different compound strategies and and five subindications of lymphoma.
This part is based on the following publication:
A Decision Support Tool for Optimizing The Lymphoma Pipeline: From Research and Development to Market

Part III: Angiogenesis
The angiogenesis affecting cancer drug report part comprises defined and up to date development strategies for 252 drugs in oncology within the portfolio of 151 companies world-wide, from Ceased to Marketed. The report extensively analyses their 177 identified drug targets, organized into 170 drug target strategies, and assesses them in 70 cancer indications.
This part is based on the following publication:
Commercializing Angiogenesis Affecting Drugs in Cancer: The Faster Route to Consider Your Options and Position of Others

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies’ pipeline and portfolio planning (PPP) in cancer by:

* Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives

* Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug’s properties

* Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities

* Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities

* Supporting development of integrative molecule, pathway and disease area strategies

* Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment

This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for cancer drugs to insure that the optimal market conditions exist by the time the products are commercialized.

Key Topics Covered:

Part I: Lung Cancer
5.1 The Scope of this Report 31
6 Consider the Therapeutic Target Among Lung Cancer Drugs for the Highest Therapeutic Outcome and Return on Investment (241 Drug Targets) 35-526
7 Emerging New Products to Established Ones: Drug Target Strategies of Lung Cancer Drugs by their Highest Stage of Development (237 Drug Target Strategies and 416 Lung Cancer Drugs) 527-817
8 Compound Strategies at Work: Competitive Benchmarking of Lung Cancer Drugs by Compound Strategy (8 Compound Strategies) 818-870
9 Selecting Subindication for Lung Cancer Drugs (Three Subindications of Lung Cancer) 871-898
10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Lung Cancer Drug Pipeline by Investigator (218 Companies) 899-1299
11 Disclaimer 1300
12 Drug Index 1301
13 Company Index 1314
Figures: Includes 7 Figures
Tables: Includes 284 Tables
Total Number of Pages: 1323

Part II: Lymphoma
5.1 The Scope of this Report 26
6 Consider the Therapeutic Target Among Lymphoma Drugs for the Highest Therapeutic Outcome and Return on Investment (181 Drug Targets) 30-387
7 Emerging New Products to Established Ones: Drug Target Strategies of Lymphoma Drugs by their Highest Stage of Development (173 Drug Target Strategies and 282 Lymphoma Drugs) 388-596
8 Compound Strategies at Work: Competitive Benchmarking of Lymphoma Drugs by Compound Strategy (8 Compound Strategies) 597-636
9 Selecting Subindication for Lymphoma Drugs (Five Subindications of Lymphoma) 637-657
10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Lymphoma Drug Pipeline by Investigator (152 Companies) 658-938
11 Disclaimer 939
12 Drug Index 940
13 Company Index 948
Figures: Includes 6 Figures
Tables: Includes 222 Tables
Total Number of Pages: 954

Part III: Angiogenesis
5.1 The Scope of this Report 37
6 Consider the Therapeutic Target Among Angiogenesis Affecting Drugs in Oncology for the Highest Therapeutic Outcome and Return on Investment (177 Drug Targets) 41-421
7 Emerging New Products to Established Ones: Drug Target Strategies of Angiogenesis Affecting Drugs in Oncology by their Highest Stage of Development (170 Drug Target Strategies and 252 Drugs) 424-666
8 Compound Strategies at Work: Competitive Benchmarking of Angiogenesis Affecting Cancer Drugs by Compound Strategy (7 Compound Strategies) 667-709
9 Selecting Indication for Angiogenesis Affecting Drugs in Oncology (70 Cancer Indications) 710-848
10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Angiogenesis Affecting Drug Pipeline in Oncology by Investigator (151 Investigators and 252 Drugs) 849-1685
12 Drug Index 1687
13 Company Index 1697
Figures: Includes 7 Figures
Tables: Includes 310 Tables
Total Number of Pages: 1,704

This Report Includes the Following Companies:
4SC
A&G Pharmaceutical
Abbott
Abiogen
Acceleron Pharma
Access
Active Biotech
Adherex
Advanomics
Advantagene
Advaxis
Advenchen
AEgera
AEterna Zentaris
Affimed Therapeutics
Agennix
Agenus
Aida Pharmaceuticals
Alchemia
Alder Biopharmaceuticals
Alethia Biotherapeutics
Alfa Wassermann
Alfacell
Allos Therapeutics
Alnylam
AlphaVax
Altor BioScience
Ambit Biosciences
Ambrilia Biopharma
Amgen
Amphora
AngioChem
Angiogen
Angiogenex
Angstrom Pharmaceuticals
Ansaris
Antisense Pharma
Antisoma
Anza Therapeutics
ApopLogic Pharmaceuticals
Apotex
Apricus Biosciences
Arana Therapeutics
Ariad
Arno Therapeutics
ArQule
Array BioPharma
Ascenta Therapeutics
Astellas
Astex Therapeutics
AstraZeneca
Attenuon
Austrianova
AVEO
Avila Therapeutics
Axelar
Bayer
Benitec
Betapharma
BioAlliance Pharma
BioAxone
Biocad
Biocon
BioCryst Pharmaceuticals
Biogen Idec
Biokine Therapeutics
Biolex
BioLineRx
BioNumerik
BioSante
Boehringer Ingelheim
Bolder BioTechnology
Borean Pharma
Bristol-Myers Squibb
BTG
Calando Pharmaceuticals
CanBas
Cancer Research Technology
CDG Therapeutics
Celator Pharmaceuticals
Celecure
Celera
Celgene
Cell Therapeutics
CellCeutix
Celldex Therapeutics
Cellmid
Celltrion
Celtic Pharma
Center of Molecular Immunology
Cephalon
CG Therapeutics
ChemoCentryx
Chemokine Therapeutics
China Sky One Medical
Chong Kun Dang
Choongwae
Circadian Technologies
Clavis Pharma
CLL Pharma
Cornerstone Pharmaceuticals
Coronado Biosciences
Critical Outcome Technologies
Cue Biotech
Curaxis
CureTech
Curis
Cyclacel
Cylene Pharmaceuticals
Cynvec
CytImmune Sciences
Cytochroma
Cytokinetics
CytRx
Daiichi Sankyo
Dainippon Sumitomo Pharma
Dara Biosciences
Deciphera Pharmaceuticals
Dendreon
Dong-A
Dr Reddy’s
Dyax
Dynavax Technologies
ECI
Eisai
Elara Pharmaceuticals
Eleos
Eli Lilly
Emergent BioSolutions
Endocyte
EntreMed
Enzon
EpiCept
Epizyme
Exelixis
ExonHit Therapeutics
Favrille
Five Prime Therapeutics
Forma Therapeutics
Fresenius
Galapagos
GammaCan
Gemin X Biotechnologies
Genencor
Genentech
Genmab
GenPat77
Genta
GenVec
Genzyme
Geron
Gilead Sciences
GlaxoSmithKline
GlobeImmune
GlycoGenesys
Gradalis
Green Cross
Hanmi
Hayashibara
Heber Biotec
HemaQuest
Hoffmann-La Roche
Human Genome Sciences
Hy BioPharma
Idera Pharmaceuticals
IGF Oncology
ImClone Systems
ImmunoCellular Therapeutics
Immunocore
ImmunoGen
Immunomedics
ImmuPharma
Incyte Corporation
Inex
Infinity Pharmaceuticals
Innate Pharma
InNexus Biotechnology
Innovive
Inovio
Insys Therapeutics
Intas Biopharmaceuticals
Intezyne Technologies
Intracel
Introgen Therapeutics
Ipsen
Isis Pharmaceuticals
Italfarmaco
Jennerex Biotherapeutics
Johnson & Johnson
KAI Pharmaceuticals
Karus Therapeutics
Kiadis
Kinex
Kirin Pharma
Kissei
Kringle Pharma
Kyowa Hakko Kirin
Lee’s Pharmaceutical
Leo
LG Life Sciences
Ligand
Lorus Therapeutics
MacroGenics
Marillion Pharmaceuticals
MAT Biopharma
Meda
MediGene
MedImmune
Medisyn Technologies
Menarini
Merck & Co
Merck KGaA
Merrimack
Mersana Therapeutics
MethylGene
Micromet
Mirna Therapeutics
MolMed
Mologen
Morvus Technology
Mycenax
Nektar Therapeutics
Nereus Pharmaceuticals
Nerviano Medical Sciences
Neurocrine Biosciences
NewSouth Innovations
NIH
Nippon Kayaku
Nippon Shinyaku
Non-industrial source
Novacea
Novartis
Novelix
Noxxon
Nycomed Pharma
Oasmia
OncoGenex Pharmaceuticals
OncoMed
Onconova
OncoTherapy Science
Oncothyreon
Orchestra Therapeutics
OSI Pharmaceuticals
Otsuka
Oxford BioMedica
OXiGENE
Paladin Labs
PanaGin
PBL Therapeutics
Pepscan Therapeutics
PepTx
Peregrine Pharmaceuticals
Pfizer
Pharmacopeia
Pharmacyclics
PharmaGap
PharmaMar
Pharmexa
Pharminox
Philogen
PhiloGene
Pierre Fabre
Piramal
Plexxikon
Portola Pharmaceuticals
Pro-Pharmaceuticals
Progen
Progen Pharmaceuticals
ProNAi Therapeutics
Protein Sciences
Protgen
PTC Therapeutics
Reata Pharmaceuticals
Receptor BioLogix
Regeneron
Regulon
Reliance Life Sciences
RESprotect
Rexahn
Rigel
Samyang
Sanofi
Sanofi-Aventis
Santaris Pharma
Sareum
SBIO
Scancell
SciClone Pharmaceuticals
Seattle Genetics
Selvita
Semafore Pharmaceuticals
ShimodaAtlantic Oncology
Shionogi
Shire
Sigma-Tau
Silence Therapeutics
Simcere Pharmaceuticals
Sirnaomics
Spear Therapeutics
SRI International
Stainwei Biotech
SuperGen
SuppreMol
Supratek Pharma
Switch Pharma
Symphogen
Synageva BioPharma
SynDevRx
Synta Pharmaceuticals
Taiho
Takeda
Talon Therapeutics
Tapestry Pharmaceuticals
Tau Therapeutics
Taxolog
Tekmira Pharmaceuticals
Telik
TetraLogic Pharmaceuticals
Teva
Thallion Pharmaceuticals
Therion Biologics
Theryte
ThromboGenics
Tigris Pharmaceuticals
Titan Pharmaceuticals
ToolGen
TopoTarget
Tracon Pharmaceuticals
Tragara Pharmaceuticals
Transgene
TriAct Therapeutics
Trion Pharma
UCB
Vaccinex
Valeant
Vaxon Biotech
VaxOnco
VBL Therapeutics
VentiRx Pharmaceuticals
Vernalis
Vertex Pharmaceuticals
Vical
Wilex
Vion Pharmaceuticals
VioQuest Pharmaceuticals
Wyeth
XBiotech
Xencor
Xerion
Xoma
Yakult Honsha
YM BioSciences
Zenotech
Zenyaku Kogyo
Zhejiang Beta Pharma
Zivena
A Shortlist of Drugs Included are:
131I-tositumomab
A6
ABT-510
afatinib
aflibercept
alemtuzumab
AMG-386
amrubicin hydrochloride
Angiozyme
apatinib
ARQ-197
astuprotimut-r
atrasentan
axitinib
belagenpumatucel-L
belinostat
belotecan hydrochloride
bevacizumab
bexarotene
BIBF-1120
BMS-690514
bortezomib
brentuximab vedotin
brivanib alaninate
canfosfamide hydrochloride
cediranib
celecoxib
cetuximab
cilengitide
cladribine
crizotinib
dacomitinib
denileukin diftitox
DI-17E6
docetaxel
dovitinib lactate
E-7820
elliptinium acetate
emepepimut-S
endostatin
ENMD-2076
enzastaurin hydrochloride
epirubicin
erlotinib
etoposide (1)
etoposide phosphate
everolimus
Exherin
foretinib
fosbretabulin tromethamine
galiximab
gefitinib
GliaAtak
GT-111
HBP-347
ibritumomab tiuxetan
icotinib hydrochloride
icrucumab
iniparib
inotuzumab ozogamicin
interferon (alpha)
interferon (alpha2b)
interferon (gamma)
interferon (gamma1b)
interferon alfa-2b
interferon alpha-2b
intetumumab
IPP-204106
irinotecan hydrochloride
JI-101
lapatinib ditosylate
lenvatinib
linifanib
LY-2275796
MGCD-265
midostaurin
mitoxantrone
motesanib diphosphate
muparfostat (IV)
nadroparin
necitumumab
NGR-TNF
nimotuzumab
obinutuzumab
oblimersen sodium
ofatumumab
ON-01910
OTS-102
paclitaxel
paclitaxel polyglumex
PancAtak
panobinostat
pazopanib hydrochloride
PCI-27483
pegdinetanib
pemetrexed disodium
PF-4856884
pixantrone
plitidepsin
ponatinib
pralatrexate
ProstAtak
PTC-299
RAF-265
ramucirumab
razoxane
Reditux
regorafenib
rhIFN-alpha
ridaforolimus
rituximab
romidepsin
sirolimus
sobuzoxane
sorafenib tosylate
SU-6668
sunitinib malate
talactoferrin alfa
TAS-102
tasquinimod
TB-403
tegafur + uracil
telatinib
temsirolimus
Tenarad
teniposide
thymalfasin
tipifarnib
tivozanib
topotecan
TRC-105
TS-1
vandetanib
vismodegib
volociximab
XL-184
XL-647
zanolimumab

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Lung Cancer, Lymphoma and Angiogenesis.
    To find out more about Triple Analysis: Lung Cancer, Lymphoma and Angiogenesis, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Lung Cancer, Lymphoma and Angiogenesis is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

Other selected research from the 'Triple Analysis' category:


Triple Analysis: Leukemia, Cancer Vaccines and Antibodies
This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Leukemia), one mechanism/target/effect area (Cancer Vaccines) and one compound specific area (Antibodies). Learn More


Triple Analysis: Colorectal Cancer, Melanoma and Prostate Cancer
This triple analysis focuses on cancer drug development strategies in Colorectal Cancer, Melanoma and Prostate Cancer. Learn More

Other selected research from the 'Oncology' category:


Cancer Vaccines Fantasy or Future?
In this newly updated progress analysis, BioSeeker not only provide a solid background and information structure, we also bring the latest within cancer vaccine achievements. Learn More


Antibodies in Oncology: Analytical Tool
This Analytical Tool transforms your computer’s desktop into a high capacity workbench within the area of antibodies in oncology. It supports you in making reports, presentations and preparing conference attendance and it is all done via an easy to use ’point and click’ interface. Learn More